<unk>  (sold under the brand name AK002) is a humanized nonfucosylated monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). In a randomized clinical trial,<unk>  was found to improve eosinophil counts and symptoms in individuals with eosinophilic gastritis and duodenitis. Adverse reactions include infusion reactions, which are mild to moderate and typically occur following the first infusion. Mechanism of action== In individuals with asthma, Siglec-8 expression is increased on the surface of eosinophils and mast cells in sputum.<unk>  depletes eosinophils via antibody-dependent natural killer cell mediated cytotoxicity. Pharmacology==<unk>  is a humanized, nonfucosylated IgG1 monoclonal antibody that targets Siglec-8. Siglec-8 is an inhibitory receptor present on eosinophils and mast cells, with low level expression on basophils. Interleukin-5, granulocyte-macrophage colony stimulating factor, and interleukin-33 enhance anti-Siglec-8 mediated destruction of eosinophils.<unk>  inhibits mast cells' IgE-mediated degranulation and de novo synthesis of prostaglandin D2 in vitro.
Lirentelimab
Regdanvimab
Atoltivimab
Nirsevimab
Bebtelovimab
Obiltoxaximab
Cemiplimab
Idarucizumab